Join the GlobalSurg | CovidSurg – Week study
Tuesday 1 September 2020
The GlobalSurg and CovidSurg collaboratives, two international surgical research networks are joining efforts to deliver GlobalSurg | CovidSurg – Week.
CovidSurg Cohort study has demonstrated the adverse outcomes of surgery in SARS-CoV-2 infected patients, achieving a publication in The Lancet. Early signals from CovidSurg-Cancer show that surgery following SARS-CoV-2 infection is associated with poor outcomes, even if surgery is several weeks after initial diagnosis. However, more granular data are needed to explore this.
GlobalSurg | CovidSurg Week is an international multi-centre cohort study that aims:
- To determine the optimal timing of surgery following SARS-CoV-2 infection;
- Determine assess key global surgical indicators, such as postoperative mortality.
In order to achieve the above aims, this study will include all patients undergoing surgery with a preoperative, postoperative or no SARS-CoV-2 infection. All hospitals are eligible to participate, regardless having admitted SARS-CoV-2 infected patients or not.
We would be delighted to have your team on board. We foresee this GlobalSurg & CovidSurg collaboration to be an expansion of the original collaboratives, that have proven to efficiently engage over 1000 hospitals and collect data from more than 35000 patients. Data collection is planned to happen for 1 week only during October 2020. We encourage you to seek your own local approvals and build local teams, involving as many specialties in your hospital as possible.
All the collaborators participating in GlobalSurg | CovidSurg – Week will be recognised with PubMed-indexed collaborative co-authorship on any resulting papers (example: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31182-X/fulltext).
Find out more here Register here